Inactivating mutations in NPC1L1 and protection from coronary heart disease.
BACKGROUND: Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann-Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding...
Main Authors: | Stitziel, N, Won, H, Morrison, A, Peloso, G, Do, R, Lange, L, Fontanillas, P, Gupta, N, Duga, S, Goel, A, Farrall, M, Saleheen, D, Ferrario, P, König, I, Asselta, R, Merlini, P, Marziliano, N, Notarangelo, M, Schick, U, Auer, P, Assimes, T, Reilly, M, Wilensky, R, Rader, D, Hovingh, G |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Massachussetts Medical Society
2014
|
Similar Items
-
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.
by: Do, R, et al.
Published: (2014) -
Loss-of-function mutations in APOC3, triglycerides, and coronary disease.
by: Crosby, J, et al.
Published: (2014) -
The role of NPC1L1 in cancer
by: Renshuai Zhang, et al.
Published: (2022-08-01) -
Targeting NPC1 in Renal Cell Carcinoma
by: Rushaniya Fazliyeva, et al.
Published: (2024-01-01) -
LMP-1 and Nasopharyngeal Carcinoma (NPC)
by: Anggun Indah Budiningrum, et al.
Published: (2014-06-01)